Cargando…
Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019
Decisions on market authorization (MA) and reimbursement have different durations across countries because of health technology assessment (HTA) procedures and negotiations between manufacturers and national authorities. To overcome this delay, France has implemented a Temporary Authorization for Us...
Autores principales: | Pham, Fiona Y.‐V., Jacquet, Emmanuelle, Taleb, Amina, Monard, Adrien, Kerouani‐Lafaye, Ghania, Turcry, Florence, Brunel, Liora, Grudé, Françoise, Yoldjian, Isabelle, Sainte‐Marie, Isabelle, Boudali, Lotfi, Blay, Jean‐Yves, Albin, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540593/ https://www.ncbi.nlm.nih.gov/pubmed/35603979 http://dx.doi.org/10.1002/ijc.34129 |
Ejemplares similares
-
Access to innovation through the national early access program and clinical trials for patients with malignant melanoma
por: Christen, Claire, et al.
Publicado: (2021) -
Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years
por: Basse, Clémence, et al.
Publicado: (2019) -
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
por: Lindner, Lars H., et al.
Publicado: (2018) -
Bilan des FIPDs COVID-19 déclarées sur e-FIT
por: Drougard, Sixtine, et al.
Publicado: (2021) -
Sorafenib with ASC‐J9(®) synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals
por: Xu, Junjie, et al.
Publicado: (2016)